Earnings summaries and quarterly performance for MAIA Biotechnology.
Executive leadership at MAIA Biotechnology.
Board of directors at MAIA Biotechnology.
Research analysts covering MAIA Biotechnology.
Recent press releases and 8-K filings for MAIA.
MAIA Biotechnology Publishes 2026 Letter to Shareholders
MAIA
New Projects/Investments
Guidance Update
- MAIA Biotechnology, Inc. published its 2026 Letter to Shareholders on February 24, 2026, detailing strong momentum in clinical trials for its lead molecule, ateganosine.
- Ateganosine, a potential breakthrough therapy for non-small cell lung cancer (NSCLC), has FDA Fast Track designation and is the first and only direct telomere-targeting anticancer agent in clinical development.
- The company's strategy targets the third-line NSCLC population, addressing an unmet need for approximately 50,000 patients annually in the United States, and sees a substantial commercial opportunity in the $50 billion global immunotherapy market.
3 days ago
MAIA Biotechnology Provides Update on Ateganosine Clinical Trials
MAIA
New Projects/Investments
Product Launch
- MAIA Biotechnology's CEO, Vlad Vitoc, M.D., published a 2026 Letter to Shareholders detailing strong momentum in clinical trials of ateganosine for non-small cell lung cancer (NSCLC).
- Ateganosine is the first and only direct telomere-targeting anticancer agent in clinical development, with its ongoing Phase 3 full approval clinical trial holding a high probability of technical success for interim and full analysis.
- The FDA has granted Fast Track designation for ateganosine as a third-line therapy for NSCLC, addressing an unmet need for approximately 50,000 patients annually in the United States.
- Ateganosine is positioned to become the foundation of a new treatment category for advanced NSCLC, with a potential commercial opportunity in a $50 billion global immunotherapy market.
3 days ago
MAIA Biotechnology Provides Update on Ateganosine Cancer Treatment Program and Outlines 2026 Milestones
MAIA
New Projects/Investments
Guidance Update
- MAIA Biotechnology secured FDA Fast Track designation for ateganosine in non-small cell lung cancer (NSCLC) and initiated a Phase 3 trial for third-line NSCLC patients in 2025.
- The company advanced its THIO-101 Phase 2 clinical trial to the Part C expansion phase, supported by a $2.3 million grant from the National Institutes of Health (NIH), and raised approximately $17.6 million from capital raises throughout 2025.
- Key milestones targeted for 2026 include initial efficacy measures from the Phase 3 study, conclusion of the Phase 2 Part C study, and continued regulatory interactions with the FDA, with potential for early commercial approval within 18 to 24 months.
Jan 20, 2026, 9:30 PM
MAIA Biotechnology Provides Update on Ateganosine Cancer Treatment Program and Outlines 2026 Milestones
MAIA
New Projects/Investments
Guidance Update
Capital Raises
- MAIA Biotechnology secured FDA Fast Track designation for ateganosine as a treatment for non-small cell lung cancer (NSCLC) and initiated a Phase 3 trial in 2025.
- The company anticipates a high probability of technical success in its pivotal Phase 3 trial, with potential for early commercial approval within 18 to 24 months.
- In 2025, MAIA raised approximately $17.6 million from capital raises.
- Key targeted 2026 milestones include expecting initial measures of efficacy from the Phase 3 study and the conclusion of Part C of the Phase 2 study.
Jan 20, 2026, 3:15 PM
MAIA Biotechnology Announces Private Placement and Phase 3 Trial Initiation
MAIA
New Projects/Investments
- MAIA Biotechnology raised $1.51 million through a private placement by issuing 1,233,488 common shares at $1.224 per share, each accompanied by a warrant, with independent directors participating to fund its Phase II THIO-101 trial and general working capital.
- The company initiated its pivotal Phase 3 THIO-104 trial for ateganosine in third-line non-small cell lung cancer (NSCLC), with the first patient dosed, building on promising Phase 2 data that demonstrated a median overall survival of 17.8 months.
- Ateganosine, which has Fast Track designation from the FDA, is positioned as a potential first-in-class telomere-targeting therapy to address a critical treatment gap in the advanced NSCLC market, projected to grow from $34 billion to $66 billion by 2032.
Jan 20, 2026, 1:00 PM
MAIA Biotechnology Directors Participate in Private Placement Offering
MAIA
New Projects/Investments
- MAIA Biotechnology announced that independent directors, including Adelina Louie Ngar Yee and Stan V. Smith, Ph.D., purchased common stock and warrants in a private placement offering that closed on December 22, 2025.
- Three directors collectively purchased 179,737 shares and 179,737 warrants at an average price of $1.224, generating gross proceeds of approximately $1.51 million.
- Directors and officers now hold a total of 5,019,857 shares, representing 13.43% of MAIA.
- This insider participation reflects strong confidence in ateganosine, MAIA's lead anticancer treatment for non-small cell lung cancer (NSCLC), for which a pivotal Phase 3 international trial was launched in December 2025.
Dec 24, 2025, 1:01 PM
MAIA Biotechnology Announces Private Placement
MAIA
Equity Offering
New Projects/Investments
- MAIA Biotechnology, Inc. announced a private placement on December 16, 2025, which is expected to close on or about December 18, 2025.
- The company will sell an aggregate of 1,233,488 shares of common stock at a purchase price of $1.224 per share, with each share offered together with a warrant to purchase one share of common stock at an exercise price of $1.36 per share.
- The gross proceeds from the offering are expected to be approximately $1.51 million.
- The net proceeds will be used to fund the execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital.
- The private placement includes participation from accredited investors and a Company director, with 179,737 shares and corresponding warrants issued to directors under the Company's 2021 Equity Incentive Plan.
Dec 17, 2025, 2:57 AM
MAIA Biotechnology Leadership Continues Insider Buying Amidst Encouraging Trial Data
MAIA
New Projects/Investments
- MAIA Biotechnology's CEO, Dr. Vlad Vitoc, and other board members acquired approximately 182,445 shares between November 21 and 28, 2025.
- This insider buying reflects confidence in the ateganosine platform, which is showing encouraging results in mid- to late-stage clinical development for advanced non-small cell lung cancer (NSCLC).
- Directors and Officers collectively hold 4,480,120 shares, representing 12.95% of the company.
Dec 11, 2025, 9:15 PM
MAIA Biotechnology Initiates Pivotal Phase 3 Trial for Ateganosine
MAIA
New Projects/Investments
- MAIA Biotechnology has initiated a pivotal Phase 3 program for its first-in-class telomere-targeting therapy, ateganosine (THIO), for advanced non-small cell lung cancer (NSCLC), with the Phase 2 trial still ongoing.
- Ateganosine is described as the only direct telomere-targeting anticancer agent currently in clinical development and has received U.S. FDA Fast Track designation for NSCLC.
- The therapy works through a dual mechanism of action that differentiates it from existing treatments, involving selective incorporation into cancer-cell telomeres and triggering an immunogenic response.
- Management indicates a very high probability of technical success for regulatory approval of ateganosine based on statistical assessments of the Phase 3 trial.
Dec 11, 2025, 6:00 PM
MAIA Biotechnology Reports Insider Share Purchases and Clinical Progress
MAIA
New Projects/Investments
- MAIA Biotechnology's CEO, Dr. Vlad Vitoc, and other board members acquired approximately 182,445 shares between November 21 and 28, 2025, demonstrating confidence in the company's ateganosine platform.
- The company's lead program, ateganosine, a telomere-targeting cancer therapy, is advancing through mid- to late-stage clinical development and continues to deliver encouraging results for non-small cell lung cancer (NSCLC).
- Directors and Officers of MAIA Biotechnology collectively hold 4,480,120 shares, representing 12.95% of the company.
Dec 11, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more